Literature DB >> 10646897

Detection of codon 12 K-ras mutations in non-neoplastic mucosa from bronchial carina in patients with lung adenocarcinomas.

T Urban1, S Ricci, C Danel, M Antoine, M Kambouchner, V Godard, R Lacave, J F Bernaudin.   

Abstract

K-ras activation by point mutation in codon 12 has been reported in lung adenocarcinomas in various models of experimental lung tumours induced by chemical carcinogens. The hypothesis of the presence of cells containing K-ras mutation in non neoplastic bronchial carina, the main site of impaction of airborne contaminants, was investigated by evaluating concurrent lung tumour and non-neoplastic proximal bronchial carinae from 19 patients with lung adenocarcinomas. The restriction fragment length polymorphism enriched PCR method used can detect one mutant allele among 10(3) normal alleles. A mutation was detected in 42% of lung adenocarcinoma samples. No mutation was detected in either tumour or bronchial carinae in nine patients (47%). K-ras mutation was detected in the lung tumour but not in bronchial carinae in four patients (21%), in both the lung tumour and bronchial carinae in four other patients (21%). In two patients (11%), K-ras mutation was detected in at least one bronchial carina, but not in the lung tumour. Mutations of codon 12, confirmed by sequencing analysis of ten samples, were G to T transversion, mostly TGT and GTT in bronchial carinae and lung tumours. Our data show that activated K-ras by point mutation can be present in non-neoplastic bronchial carina mucosa even when no mutation is detected in tumour samples.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10646897      PMCID: PMC2363273          DOI: 10.1054/bjoc.1999.0935

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  43 in total

1.  Changes in bronchial epithelium in relation to cigarette smoking, 1955-1960 vs. 1970-1977.

Authors:  O Auerbach; E C Hammond; L Garfinkel
Journal:  N Engl J Med       Date:  1979-02-22       Impact factor: 91.245

2.  Association of point mutation in c-Ki-ras oncogene in lung adenocarcinoma with particular reference to cytologic subtypes.

Authors:  T Kobayashi; H Tsuda; M Noguchi; S Hirohashi; Y Shimosato; T Goya; Y Hayata
Journal:  Cancer       Date:  1990-07-15       Impact factor: 6.860

Review 3.  ras genes.

Authors:  M Barbacid
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

4.  DNA base changes in benzo[a]pyrene diol epoxide-induced dihydrofolate reductase mutants of Chinese hamster ovary cells.

Authors:  A M Carothers; D Grunberger
Journal:  Carcinogenesis       Date:  1990-01       Impact factor: 4.944

5.  Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung.

Authors:  S Rodenhuis; R J Slebos; A J Boot; S G Evers; W J Mooi; S S Wagenaar; P C van Bodegom; J L Bos
Journal:  Cancer Res       Date:  1988-10-15       Impact factor: 12.701

Review 6.  ras oncogenes in human cancer: a review.

Authors:  J L Bos
Journal:  Cancer Res       Date:  1989-09-01       Impact factor: 12.701

7.  Rapid detection of ras oncogenes in human tumors: applications to colon, esophageal, and gastric cancer.

Authors:  W Jiang; S M Kahn; J G Guillem; S H Lu; I B Weinstein
Journal:  Oncogene       Date:  1989-07       Impact factor: 9.867

8.  Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma.

Authors:  G C Burmer; L A Loeb
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

9.  Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse.

Authors:  M You; U Candrian; R R Maronpot; G D Stoner; M W Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

10.  Codon 12 Ki-ras mutation in non-small-cell lung cancer: comparative evaluation in tumoural and non-tumoural lung.

Authors:  T Urban; S Ricci; R Lacave; M Antoine; M Kambouchner; F Capron; J F Bernaudin
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

View more
  4 in total

Review 1.  Targeted therapies: how personal should we go?

Authors:  Miriam Martini; Loredana Vecchione; Salvatore Siena; Sabine Tejpar; Alberto Bardelli
Journal:  Nat Rev Clin Oncol       Date:  2011-11-15       Impact factor: 66.675

2.  Topographic analysis of K- ras mutations in histologically normal lung tissues and tumours of lung cancer patients.

Authors:  P Keohavong; H H Mady; W M Gao; J M Siegfried; J D Luketich; M F Melhem
Journal:  Br J Cancer       Date:  2001-07-20       Impact factor: 7.640

3.  Detection of oncogenic mutations in resected bronchial margins by next-generation sequencing indicates early relapse in stage IA lung adenocarcinoma patients.

Authors:  Tangfeng Lv; Jiawei Zou; Hongbing Liu; Qin Shen; Zhenfeng Lu; XiaoJun Zhou; Xiaonan Wang; Yong Song
Journal:  Oncotarget       Date:  2017-06-20

4.  Targeted next-generation sequencing reveals recurrence-associated genomic alterations in early-stage non-small cell lung cancer.

Authors:  William C S Cho; Kien Thiam Tan; Victor W S Ma; Jacky Y C Li; Roger K C Ngan; Wah Cheuk; Timothy T C Yip; Yi-Ting Yang; Shu-Jen Chen
Journal:  Oncotarget       Date:  2018-11-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.